Suppr超能文献

一种靶向致癌转录因子的计算药物重新定位方法。

A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.

作者信息

Gayvert Kaitlyn M, Dardenne Etienne, Cheung Cynthia, Boland Mary Regina, Lorberbaum Tal, Wanjala Jackline, Chen Yu, Rubin Mark A, Tatonetti Nicholas P, Rickman David S, Elemento Olivier

机构信息

Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY 10021, USA; Institute for Precision Medicine, Weill Cornell Medical College, New York, NY 10021, USA; Tri-Institutional Training Program in Computational Biology and Medicine, New York, NY 10065, USA.

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA.

出版信息

Cell Rep. 2016 Jun 14;15(11):2348-56. doi: 10.1016/j.celrep.2016.05.037. Epub 2016 Jun 2.

Abstract

Mutations in transcription factor (TF) genes are frequently observed in tumors, often leading to aberrant transcriptional activity. Unfortunately, TFs are often considered undruggable due to the absence of targetable enzymatic activity. To address this problem, we developed CRAFTT, a computational drug-repositioning approach for targeting TF activity. CRAFTT combines ChIP-seq with drug-induced expression profiling to identify small molecules that can specifically perturb TF activity. Application to ENCODE ChIP-seq datasets revealed known drug-TF interactions, and a global drug-protein network analysis supported these predictions. Application of CRAFTT to ERG, a pro-invasive, frequently overexpressed oncogenic TF, predicted that dexamethasone would inhibit ERG activity. Dexamethasone significantly decreased cell invasion and migration in an ERG-dependent manner. Furthermore, analysis of electronic medical record data indicates a protective role for dexamethasone against prostate cancer. Altogether, our method provides a broadly applicable strategy for identifying drugs that specifically modulate TF activity.

摘要

转录因子(TF)基因的突变在肿瘤中经常被观察到,这往往会导致异常的转录活性。不幸的是,由于缺乏可靶向的酶活性,转录因子通常被认为是不可成药的。为了解决这个问题,我们开发了CRAFTT,一种用于靶向转录因子活性的计算药物重新定位方法。CRAFTT将染色质免疫沉淀测序(ChIP-seq)与药物诱导的表达谱分析相结合,以识别能够特异性干扰转录因子活性的小分子。应用于ENCODE ChIP-seq数据集揭示了已知的药物-转录因子相互作用,全局药物-蛋白质网络分析支持了这些预测。将CRAFTT应用于ERG(一种促侵袭、经常过度表达的致癌转录因子),预测地塞米松会抑制ERG活性。地塞米松以ERG依赖的方式显著降低细胞侵袭和迁移。此外,电子病历数据分析表明地塞米松对前列腺癌具有保护作用。总之,我们的方法为识别特异性调节转录因子活性的药物提供了一种广泛适用的策略。

相似文献

1
A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.
Cell Rep. 2016 Jun 14;15(11):2348-56. doi: 10.1016/j.celrep.2016.05.037. Epub 2016 Jun 2.
3
Cell-Based Methods for the Identification of Myc-Inhibitory Small Molecules.
Methods Mol Biol. 2021;2318:337-346. doi: 10.1007/978-1-0716-1476-1_19.
4
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Oncotarget. 2015 Feb 10;6(4):2407-20. doi: 10.18632/oncotarget.2964.
8
Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Int J Oncol. 2018 Dec;53(6):2503-2517. doi: 10.3892/ijo.2018.4577. Epub 2018 Sep 27.
10
Cell-based methods for the identification of MYC-inhibitory small molecules.
Methods Mol Biol. 2013;1012:255-64. doi: 10.1007/978-1-62703-429-6_18.

引用本文的文献

1
Improving drug repositioning with negative data labeling using large language models.
J Cheminform. 2025 Feb 4;17(1):16. doi: 10.1186/s13321-025-00962-0.
2
approaches for drug repurposing in oncology: a scoping review.
Front Pharmacol. 2024 Jun 11;15:1400029. doi: 10.3389/fphar.2024.1400029. eCollection 2024.
3
Validation approaches for computational drug repurposing: a review.
AMIA Annu Symp Proc. 2024 Jan 11;2023:559-568. eCollection 2023.
4
Pan-cancer analyses reveal multi-omic signatures and clinical implementations of the forkhead-box gene family.
Cancer Med. 2023 Aug;12(16):17428-17444. doi: 10.1002/cam4.6312. Epub 2023 Jul 4.
5
PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal.
Curr Med Chem. 2024;31(22):3265-3285. doi: 10.2174/0929867330666230607104441.
6
Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer.
ACS Omega. 2022 Dec 29;8(1):56-73. doi: 10.1021/acsomega.2c05821. eCollection 2023 Jan 10.
7
Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.
Cancers (Basel). 2022 Feb 22;14(5):1118. doi: 10.3390/cancers14051118.
8
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
Med Sci (Basel). 2022 Feb 18;10(1):15. doi: 10.3390/medsci10010015.
9
Proteasome regulators in pancreatic cancer.
World J Gastrointest Oncol. 2022 Jan 15;14(1):38-54. doi: 10.4251/wjgo.v14.i1.38.
10
Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network.
Cancer Biol Med. 2021 Apr 24;19(1):74-89. doi: 10.20892/j.issn.2095-3941.2020.0218.

本文引用的文献

1
Fast randomization of large genomic datasets while preserving alteration counts.
Bioinformatics. 2014 Sep 1;30(17):i617-23. doi: 10.1093/bioinformatics/btu474.
2
PiHelper: an open source framework for drug-target and antibody-target data.
Bioinformatics. 2013 Aug 15;29(16):2071-2. doi: 10.1093/bioinformatics/btt345. Epub 2013 Jun 12.
3
Interpretation of genomic variants using a unified biological network approach.
PLoS Comput Biol. 2013;9(3):e1002886. doi: 10.1371/journal.pcbi.1002886. Epub 2013 Mar 7.
4
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.
5
A comprehensive nuclear receptor network for breast cancer cells.
Cell Rep. 2013 Feb 21;3(2):538-51. doi: 10.1016/j.celrep.2013.01.004. Epub 2013 Jan 31.
7
Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer.
Cell Cycle. 2012 Sep 15;11(18):3380-3. doi: 10.4161/cc.21401. Epub 2012 Aug 23.
8
Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.
Oncogene. 2013 Jun 20;32(25):3039-48. doi: 10.1038/onc.2012.321. Epub 2012 Aug 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验